A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial

被引：0

作者：

Naoto Takahashi

Mitsuro Kanda

Takaki Yoshikawa

Nobuhiro Takiguchi

Kazumasa Fujitani

Katsufumi Miyamoto

Yuichi Ito

Osamu Takayama

Motohiro Imano

Norio Mitsumori

Junichi Sakamoto

Satoshi Morita

Yasuhiro Kodera

机构：

[1] Kashiwa Hospital,Department of Surgery, Jikei University School of Medicine

[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)

[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery

[4] Chiba Cancer Center,Division of Gastroenterological Surgery

[5] Osaka Prefectural General Medical Center,Department of Surgery

[6] Hyogo Prefectural Awaji Medical Center,Department of Surgery

[7] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery

[8] Itami City Hospital,Department of Surgery

[9] Kinki University,Department of Surgery, Faculty of Medicine

[10] Jikei University School of Medicine,Department of Surgery

[11] Tokai Central Hospital,Department of Biomedical Statistics and Bioinformatics

[12] Kyoto University Graduate School of Medicine,undefined

来源：

Gastric Cancer | 2018年 / 21卷

关键词：

Gastric cancer; Intraperitoneal administration; Paclitaxel; Peritoneal metastasis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1014 / 1023

页数：9

共 43 条

[31] Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Fayette, J.
Cropet, C.
Gautier, J.
Toullec, C.
Vinches, M.
Burgy, M.
Iacob, M.
Kaminsky-Forrett, M-C.
Salas, S.
Linot, B.
Champagnac, A.
Sondarjee, I.
Pechery, A.
Perol, D.
Bourhis, J.
ANNALS OF ONCOLOGY, 2024, 35 : S623 - S623
[32] Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Concin, Nicole
Braicu, Loana
Berger, Regina
Mahner, Sven
Sehouli, Jalid
Zeimet, Alain G.
Pujade-Lauraine, Eric
Cassier, Philippe Alexandre
Moll, Ute Martha
Ulmer, Hanno
Leunen, Karin
Marth, Christian
Vergote, Ignace
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] TEMOZOLOMIDE (TMZ) CAN BE SAFELY ADMINISTERED IN THE IMMEDIATE POSTOPERATIVE PERIOD AFTER TUMOR RESECTION AND GLIADEL ® WAFER PLACEMENT IN PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS: FINAL RESULTS OF A PROSPECTIVE, MULTI-INSTITUTIONAL, PHASE I/II TRIAL
Sumrall, Ashley L.
Burri, Stuart
Brick, Wendy
Asher, Anthony
NEURO-ONCOLOGY, 2012, 14 : 66 - 66
[34] Efficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274
Volkova, M., I
Olshanskaya, A. S.
Kalinin, S. A.
ONKOUROLOGIYA, 2021, 17 (01): : 108 - 119
[35] Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Yang, Chuting
Zheng, Yaling
Song, Chaoyang
Wu, Ming
Wang, Lei
Zhou, Xuan
Yue, Chunyan
Lin, Xiaonan
Chen, Jie
Zeng, Hui
Huang, Rui
Li, Yuhua
BLOOD, 2023, 142
[36] The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
Guerif, Stephane Gilles
Latorzeff, Igor
Roca, Lise
Allouache, Djelila
Supiot, Stephane
Lagneau, Edouard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[37] Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC).
Aitchison, M.
Bray, C. A.
Van Poppel, H.
Sylvester, R.
Graham, J.
Innes, C.
McMahon, L.
Vasey, P. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[38] Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
Fayette, Jerome
Cropet, Claire
Gautier, Julien
Toullec, Clemence
Burgy, Mickael
Bruyas, Amandine
Sire, Christian
Lagrange, Aurelie
Clatot, Florian
Calderon, Benoit
Vinches, Marie
Iacob, Mariana
Martin, Laurent
Berard, Eve Marie Neidhardt
Kaminsky, Marie-Christine
Vansteene, Damien
Salas, Sebastien
Champagnac, Anne
Perol, David
Bourhis, Jean
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.
Wu, Zheng
Wang, Zheng
Zhang, Lei
Song, Xiaojing
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 513 - 513
[40] Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
Wang, Zheng
Zhang, Lei
Song, Xiaojing
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 588 - 588

← 1 2 3 4 5 →